Bayer Schering Pharma has completed its first global phase-II study analyzing the sensitivity and specificity of BAY 94-9172 (AV1/ZK). The study used positron emission tomography (PET) in patients with probable Alzheimer’s disease, as compared to healthy volunteers.
BAY 94-9172 binds to the beta amyloid protein in the brain, a pathological hallmark of Alzheimer’s disease. The data is being analyzed and results will be presented at this year’s International Conference on Alzheimer’s Disease (ICAD) in Vienna.
Bayer Schering Pharma has extended its Phase-II program to further expand the number of imaged individuals, and will also begin its pivotal Phase-III global clinical development program of BAY 94-9172 soon.